(NewsDirect)
- Collaboration will explore trans-arterial delivery ofImugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapyplatform.
- TAMP enables localized, targeted delivery of CF33 todifficult-to-access tumors, such as pancreatic and liver tumors.
Los Altos, Californiaand Sydney, Australia, July 20, 2023 ( 500NewsWire ) -- RenovoRx, Inc . (“RenovoRx”)(Nasdaq: RNXT), a clinical-stage biopharmaceutical company developingtargeted combination therapies, and Imugene Ltd (“Imugene”)(ASX: IMU), a clinical-stage immuno-oncology company, today announceda strategic research collaboration to optimize the delivery ofImugene’s oncolytic virus therapy with RenovoRx’s TAMP(Trans-Arterial Micro-Perfusion) therapy platform for the treatment ofdifficult-to-access tumors.
“We believe the synergy between RenovoRx’s trans-arterialdrug delivery system and our CF33 oncolytic virus platform has thepotential to facilitate treatment of difficult-to-access cancers andhelp patients,” said Leslie Chong, Managing Director & ChiefExecutive Officer of Imugene.
“Our collaboration with Imugene is an important milestone forRenovoRx as we expand our pipeline from exclusively treating locallyadvanced disease to treating metastatic disease with immunotherapy,”said Shaun Bagai, Chief Executive Officer, RenovoRx. “We lookforward to combining our proprietary TAMP platform with Imugene’sCF33 oncolytic virus with the goal of optimizing clinical benefits forpatients.”
As part of thecollaboration, Imugene and RenovoRx will investigate the ability toadminister Imugene’s CF33 oncolytic virus technology withRenovoRx’s TAMP therapy platform. The ability to treatdifficult-to-access tumours, such as pancreatic and liver cancers, bydelivering CF33 trans-arterially may be valuable to cancer patientscompared to traditional administration methods where dense fibroustissue and lack of blood vessels supplying the tumours have been shownto limit therapy uptake.
The TAMPplatform is designed to ensure precise therapeutic delivery to atarget tissue. In previous studies, the proprietary platformdemonstrated a 100-fold (two orders of magnitude) increase in localtissue concentration with TAMP compared to conventional IV delivery aswell as advantages compared to off-the-shelf intra-arterial (IA)delivery. TAMP’s unique approach to treatment delivery offers thepotential to increase an oncology therapy’s efficacy, improvesafety, and widen its therapeutic window by focusing its distributionuniformly in target tissue.
RenovoRx won the Drug Delivery Technology category of the FierceInnovation Awards – Life Sciences Edition 2020 for its TAMPtherapy platform technology.
About Imugene (ASX: IMU)
Imugene Limited is a clinical stageimmuno-oncology company developing a range of new and novelimmunotherapies that seek to activate the immune system of cancerpatients to treat and eradicate tumors. Imugene’s unique platformtechnologies seek to harness the body’s immune system againsttumors, potentially achieving a similar or greater effect thansynthetically manufactured monoclonal antibody and otherimmunotherapies. Imugene’s product pipeline includes multipleimmunotherapy B-cell vaccine candidates and an oncolytic virotherapy(CF33) aimed at treating a variety of cancers in combination withstandard of care drugs and emerging immunotherapies such as CAR T’sfor solid tumors. Imugene is supported by a leading team ofinternational cancer experts with extensive experience in developingnew cancer therapies with many approved for sale and marketing forglobal markets.
Imugene’svision is to help transform and improve the treatment of cancer andthe lives of the millions of patients who need effective treatments.This vision is backed by a growing body of clinical evidence andpeer-reviewed research. Imugene is well funded and resourced, todeliver on its commercial and clinical milestones. Together withleading specialists and medical professionals, Imugene believes itsimmuno-oncology therapies will become foundation treatments forcancer. Imugene’s goal is to ensure that Imugene and itsshareholders are at the forefront of this rapidly growing globalmarket.
About RenovoRx,Inc.
RenovoRxis a clinical-stage biopharmaceutical company developing targetedcombination therapies for high unmet medical needs. The Company’sproprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platformis designed to bypass traditional systemic delivery methods and ensureprecise therapeutic delivery to a target tissue, while minimizing atherapy’s systemic toxicities. RenovoRx’s unique approach todrug-delivery offers the potential for increased treatment safety,tolerance, and wider therapeutic windows. The Company’s lead productcandidate, RenovoGem™, combines gemcitabine with the company’spatented delivery system and is regulated by FDA under its 505(b)2pathway. RenovoGem is currently in a Phase III clinical trial(TIGeR-PaC) for the treatment of locally advanced pancreatic cancer,where it observed a 6-month median Overall Survival benefit and 65%reduction in adverse events at its interim analysis by delivering ageneric chemotherapy alone. RenovoRx is committed to transforming thelives of patients by delivering innovative solutions to change thecurrent paradigm of cancer care. For more information, visit www.renovorx.com . Follow RenovoRxon , and .
Forward-LookingStatements
This press release contains forward-looking statements withinthe meaning of Section 27A of the Securities Act of 1933, and Section21E of the Securities Exchange Act of 1934, including but not limitedto statements regarding the collaboration between RenovoRx and ImugeneLimited. Statements that are not purely historical are forward-lookingstatements. The forward-looking statements contained herein are basedupon our current expectations and beliefs regarding future events,many of which, by their nature, are inherently uncertain, outside ofour control and involve assumptions that may never materialize or mayprove to be incorrect. These may include estimates, projections andstatements relating to our research and development plans, clinicaltrials, therapy platform, business plans, objectives and expectedoperating results, which are based on current expectations andassumptions that are subject to known and unknown risks anduncertainties that may cause actual results to differ materially fromthose expressed or implied by these forward-looking statements. Thesestatements may be identified using words such as “may,”“expects,” “plans,” “aims,” “anticipates,”“believes,” “forecasts,” “estimates,” “intends,” and“potential,” or the negative of these terms or other comparableterminology regarding RenovoRx’s expectations strategy, plans orintentions, although not all forward-looking statements contain thesewords. These forward-looking statements are subject to a number ofrisks, uncertainties and assumptions, that could cause actual eventsto differ materially from those projected or indicated by suchstatements, including, among other things: the timing of theinitiation, progress and potential results of our preclinical studies,clinical trials and our research programs; the interim results may notbe predictive of the outcome of our clinical trial, which may notdemonstrate sufficient safety and efficacy to support regulatoryapproval of our product candidate, or the regulatory authority maydisagree with our interpretation of the data; research and clinicaldevelopment plans and timelines, and the regulatory process for ourproduct candidates; future potential regulatory milestones for ourproduct candidates, including those related to current and plannedclinical studies; our ability to use and expand our therapy platformto build a pipeline of product candidates; our ability to advanceproduct candidates into, and successfully complete, clinical trials;the timing or likelihood of regulatory filings and approvals; ourestimates of the number of patients who suffer from the diseases weare targeting and the number of patients that may enroll in ourclinical trials; the commercialization potential of our productcandidates, if approved; our ability and the potential to successfullymanufacture and supply our product candidates for clinical trials andfor commercial use, if approved; future strategic arrangements and/orcollaborations and the potential benefits of such arrangements; ourestimates regarding expenses, future revenue, capital requirements andneeds for additional financing and our ability to obtain additionalcapital; the sufficiency of our existing cash and cash equivalents tofund our future operating expenses and capital expenditurerequirements; our ability to retain the continued service of our keypersonnel and to identify, hire and retain additional qualifiedpersonnel; the implementation of our strategic plans for our businessand product candidates; the scope of protection we are able toestablish and maintain for intellectual property rights, including ourtherapy platform, product candidates and research programs; ourability to contract with third-party suppliers and manufacturers andtheir ability to perform adequately; the pricing, coverage andreimbursement of our product candidates, if approved; developmentsrelating to our competitors and our industry, including competingproduct candidates and therapies; negative impacts of the ongoingCOVID-19 pandemic on our operations; and other risks. Informationregarding the foregoing and additional risks may be found in thesection entitled “Risk Factors” in documents that we file fromtime to time with the Securities and Exchange Commission.
Forward-lookingstatements included herein are made as of the date hereof, andRenovoRx does not undertake any obligation to update publicly suchforward-looking statements to reflect subsequent events orcircumstances, except as required by law.
For more information, pleasecontact:
RenovoRx
InvestorContact:
KCSAStrategic Communications
Valter Pinto or Jack Perkins
T:212-896-1254
Media Contact:
KKH Advisors
Kimberly Ha
T: 917 291-5744
ImugeneLimited
LeslieChong
ManagingDirector and Chief Executive Officer
Follow us on Twitter@TeamImugene
Likeus on Facebook @Imugene
Connect withus on LinkedIn @Imugene Limited
ContactDetails
Kimberly Ha
+1 917-291-5744
Copyright (c) 2023 TheNewswire - All rights reserved.